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Abstract:  
Background: Although clinicians encounter antimycobacterial treatment in Human 
Immunodeficiency (HIV)-infected children as one of the most common treatments coadministered 
with antiretroviral treatment (ART), quantitative data on the extent of antimycobacterial treatment 
among HIV-infected children at the time of commencement of ART and at different times during 
ART is scarce. The baseline risk factors associated with being on both ART and antimycobacterial 
treatments are not known and it remains to be elucidated how the different exposure factors impact on 
the antimycobacterial treatment-free survival of children who begin ART without antimycobacterial 
treatment.  
Objectives: To describe the prevalence of antimycobacterial treatment among children at the time of 
starting ART and the antimycobacterial treatment-free survival after starting ART. 
Design: A retrospective cohort study based on record reviews at the Harriet Shezi children‘s clinic 
(HSCC). 
Population: HIV-infected children less than fifteen years of age presumed ART naïve started on ART 
at HSCC. 
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Analysis: A descriptive analysis of the prevalence of antimycobacterial treatment at time of start of 
ART was done. Kaplan Meier (KM) survival curves were used to determine the antimycobacterial 
treatment-free survival and logistic regression was used to analyze the association between baseline 
factors and future antimycobacterial treatment among children who had no antimycobacterial 
treatment at time of start of ART. 
Results: The prevalence of antimycobacterial treatment at the time of starting ART was 518/1941 
(26.7%, 95% confidence interval (CI): 24.7-28.7). Among children who started ART without 
antimycobacterial treatment, the KM cumulative probability of antiretroviral and antimycobacterial 
(ART/antimycobacterial) co-treatment in the first 3 months of starting ART was 4.6% (95% CI: 4.1-
5.2), in the first 12 months it was 18.1% (95% CI: 17.0-19.2) and in the first 24 months of starting 
ART it was 24% (95% CI: 21.9-25.1). Survival analysis suggested that children with high baseline  
viral load, advanced World Health Organization (WHO) stage of disease, very low normalized weight 
for age (waz) and very young age (less than one year) at start of ART had significantly reduced 
antimycobacterial treatment-free survival (log rank p < 0.05) in the first two years of starting ART. In 
the logistic regression model, age less than one year {Odds ratio (OR): 3.7 (95% CI: 2.2-6.0; p < 
0.0001)} and very low weight for age Z-score (waz < -3) {OR; 2.2 (95% CI: 1.4-3.6; p = 0.0015)} 
were the two critical risk factors independently associated with future antimycobacterial treatment.  
 Conclusions: Antimycobacterial treatment is extremely common among HIV-infected children at the 
time of starting ART and early after starting ART and the incremental risk of being on 
ART/antimycobacterial co-treatment decreases with time on ART. The results emphasize the need for 
a heightened and careful alertness for mycobacterial events especially among children starting ART 
with severe malnutrition and those who start ART at age less than one year. The results further 
suggest that it is probably optimal to start ART in children before their nutritional status has 
deteriorated severely in the course of the HIV disease so that they get protection against mycobacterial 
events by early ART. 
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CHAPTER 1: INTRODUCTION 
 
Background:  
 
ART provided as part of chronic HIV care has been shown in observational studies to reduce the 
incidence rate of TB among HIV-infected adults in South Africa by about 70 to 90% (Lawn, Badri & 
Wood, 2005; Maher, Harries & Getahun, 2005; Miranda et al. 2007) and among children by about 
70% (Martinson et al. 2009; Edmonds et al. 2009). Despite this, clinicians still encounter TB as the 
commonest opportunistic infection in HIV-infected persons before starting ART and while they are 
receiving ART (Lawn, Wilkinson, Lipman & Wood, 2008). 
In the early years of ART there was little evidence about the benefits of concurrent administration of 
ART and antimycobacterial treatment and a significant proportion of physicians treating both 
conditions were skeptical about giving the treatments together simultaneously. Some treatment 
guidelines were emphasizing completion of TB treatment before starting ART for those whose CD4 
was above 200 cells/µl while on TB treatment or at least completing the intensive phase of TB 
treatment before ART initiation if the CD4 was between 100 and 200cells/µL and for those who had 
CD4 count less than 100cells/µL there was no clear consensus and in such cases ART was only 
introduced as soon as it was practicable (BHIVA, 2005). A retrospective study in the United Kingdom 
(Dean et al. 2002), recommended starting ART early after initiation of TB therapy for patients with 
advanced HIV disease (CD4 < 100 cells/µl) and to defer ART until the continuation phase of TB 
therapy (i.e. after 2 months) for patients who are clinically stable (CD4 > 100 cells/µl). 
Recent studies have however clearly shown the overwhelming benefits of ART/antimycobacterial co-
administration in patients with HIV/TB co-morbidity on mortality (Karim et al. 2010; Violari et al. 
2008; Velasco et al. 2009; Varma et al. 2009) and morbidity (Edmonds et al. 2009; Dean et al. 2002). 
Results from a randomized clinical trial in South Africa (Karim et al. 2010) reported significantly 
reduced mortality among the 425 patients (5.4/100 person years, or 25 patients) in the pooled ‗early 
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integrated arm‘ (ART within two weeks of TB treatment) and ‗delayed integrated arm‘ (after two 
months of TB treatment) compared to that among the 213 patients in the ‗sequential arm‘ (ART after 
completion of TB treatment) (12.1/100 person years, or 27 patients), p <0.005. Similarly, an 
observational prospective study in Spain reported that starting ART in the first two months of TB 
treatment was an independent predictor of survival (HR: 0.37, 95% CI 0.17-0.66) when compared to 
initiation after three months of TB treatment (Velasco et al. 2009). Another prospective study in 
Thailand also demonstrated an increased risk of death the longer ART was delayed (HR 9.0, 95% CI 
1.1-73.0) for those for whom ART was delayed compared to those who initiated ART within the first 
120 days of TB treatment (Varma et al. 2009). In South Africa, it was reported from a large 
retrospective study, that starting ART within the first 30 days of TB treatment did not increase 
mortality (HR 1.28, 95% CI 0.78-2.10) compared to 31 to 60 days (HR: 1.08, 95% CI 0.59-1.98), 61-
120 days (HR:0.89, 95% CI 0.48-1.63) and >120days (HR: 1.25, 95% CI 0.65-2.43) (Westreich et al. 
2009). In the United Kingdom it was shown from a retrospective cohort that ART during TB 
treatment was associated with significant reductions in viral load and AIDS-defining illness (3.5 
versus 24.5%; relative risk (RR) = 0.14) and mortality (Dean et al. 2002). 
Although this may be the case, there are concerns about adherence (Nachega et al. 2008), high pill 
burden, drug interactions (Boulle et al. 2008; Jaspan et al. 2007) and overlapping toxicity which is 
seen especially with nevirapine-based ART regimens (Nachega et al. 2008; Lawn et al. 2008).  
Because of the weighted benefits of ART/antimycobacterial cotreatment provided by the new 
evidence, several national guidelines including the South African (DOH, 2009) have been adopted to 
start ART as soon as it can be tolerated after starting antimycobacterial treatment and this is usually 
within two to eight weeks. 
Although the HIV and mycobacterial co-infection is a huge public health problem in children in as far 
as the dual management of the two co-morbidities and the high frequency are concerned, quantitative 
data on the extent of ART/antimycobacterial co-treatment among children is lacking.  
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Justification for the study: 
   
This study is done in South Africa where a high number of TB patients are also HIV-infected (WHO 
report, 2009) and therefore warranting dual therapy for the two conditions. In order to help managers 
and to plan resource allocation it is important to quantify the needs of HIV-infected children for 
antimycobacterial treatment at different phases in their encounter with HIV treatment services, 
including prior to initiating ART and during the early and later phases of ART.  
Co-treatment of HIV and mycobacterial infections in children is complex due to some of the reasons 
mentioned above and requires modification of ART regimens in some cases (Lawn & Wood, 2006) 
and careful monitoring. For this reason, it is important to determine the extent of the co-treatment so 
that policy makers can design appropriate algorithms in the area of ART/antimycobacterial co-
treatment. The limitations posed by the above mentioned complexities of ART/antimycobacterial co-
treatment make the South African public sector paediatric HIV clinician quickly exhaust the only 
available option for ART among the very young children on antimycobacterial treatment, two 
nucleoside reverse transcriptase inhibitors (NRTIs) and the one available protease inhibitor (PI) in 
children, Kaletra (ritonavir boosted lopinavir). It is therefore important to quantify the extent of the 
problem so that governments can plan drug supplies and bargain with pharmaceutical companies for 
affordable prices of better drugs for co-treatment of HIV and mycobacteria.  
In addition to planning for medicines, knowledge of the extent of the requirements of the dually 
infected children also puts public health officials and policy makers in a picture to see and possibly 
appreciate the need for newer and more efficient mycobacterial diagnostic interventions.  
HIV clinicians also need to know how much antimycobacterial treatment there is at the start and after 
starting ART and the risk factors associated with starting antimycobacterial treatment among children 
on ART so that they can provide quality care to their patients and public health managers can also 
plan to adopt HIV/TB control measures at community level. Knowledge of the baseline risk factors 
associated with future mycobacterial events among children on ART can also help physicians to make 
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rough forecasts of the events to be anticipated for and help them to prepare. It is also very important 
for physicians to know the critical times to do follow up of high risk children groups so that they are 
not caught unawares when such events arise.  
CHAPTER 2: LITERATURE REVIEW 
 
The millennium development goal target 6.c wishes for the TB incidence to decrease by half by 2015 
from baseline level in 1990 but in reality the global incidence of TB has been rising since 1990 from 
6.6 million cases to 8.3 million cases in 2000, to 9.24 million cases in 2006 and 9.27 million cases in 
2007 (WHO report, 2009). Approximately 31% of these cases were from the Africa region and about 
15% of the total 9.27 million cases were HIV-infected (WHO report, 2009). Of the HIV-infected 
incident TB cases approximately 79% were from the African region (WHO report, 2006; WHO report, 
2009). South Africa and Nigeria occupy positions in the top five of the worst TB burdened countries 
in the world both with 0.46 million cases in 2007 (WHO report, 2009). Of the total incident TB cases 
annually, it is further estimated that 11% are childhood TB cases (age less than 15 years) of which 
75% of the childhood cases occur annually in 22 high-burden countries. It is further estimated that the 
22 high burden countries together account for 80% of the world‘s estimated incident TB cases (WHO, 
2006). 
South Africa has a high TB case notification rate (CNR). Because of difficulties in diagnosis, 
especially among children, and record ambiguity, the CNR actually reflects the cases that were given 
antimycobacterial treatment (for any reason) but not the true incidence of TB disease (Marais et al. 
2006). The national CNR has risen from 169/100000 population in 1998 to 722/100000 in 2006 
(National Department of Health (DOH), 2006). KwaZulu-Natal had the highest rise in CNR from 
110/100000 to 1075/100000 followed by Western Cape from 464/100000 to 1030/100000 while the 
CNR in Gauteng rose from 123/100000 to 500/100000 in the same period (DOH, 2006) and this is 
attributed mainly to HIV. A Cape Town study in two socioeconomically disadvantaged communities 
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revealed a high CNR of TB in children less than five years (3588/100000), which was about 3.5 times 
that in adults and the 0-14 year age group contributed 39% of the total caseload (van Rie et al. 1999). 
The Joint United Nations HIV/AIDS programme (UNAIDS), (2007), estimated the new annual HIV 
infections in children less than 15 years globally to be between 390000-420000. In South Africa 
among children between 2 and 14 years the 2008 prevalence of HIV was 2.5% CI; 1.9-3.5. (South 
Africa National HIV Prevalence, Incidence, Behavior and Communication Survey, 2008). 
TB/HIV Collaboration 
The TB/HIV collaboration being implemented by several national programmes is seen as a feasible 
policy strategy to tackle the serious impairments in the national TB programmes, to improve the 
quality and continuity of care of patients with HIV/TB co-morbidities and provide joint planning, 
monitoring and interpretation of progress towards TB and HIV control targets (Maher et al, 2005; 
WHO report, 2008; WHO, 2004). This strategy involves HIV testing and counseling among TB 
patients and providing interventions including cotrimoxazole prophylaxis (CPT), isoniazid preventive 
therapy (IPT) and ART to those HIV-infected and eligible. The strategy also involves TB screening, 
detection, ensuring infection control in health care and congregate settings and treatment of TB and 
other interventions for HIV related opportunistic infections among those that are found HIV-infected 
(WHO, 2004).   
Influence of HIV on TB and diagnosis of TB in HIV-infected clients  
 
HIV weakens the immune system and promotes the progression of latent to active TB (Mofenson et 
al. 2004; Cohen et al. 2006). It promotes the progression of recently acquired TB infection to active 
disease (Zar et al. 2006). HIV increases the rate of TB re-infection (Maartens, 2000) and relapses and 
increases the rate of transmission in the community (Maher et al. 2005). Children with HIV infection 
are at higher risk of more severe forms of TB (De Cock, Grant & Porter, 1995) and treatment 
outcomes are worse compared to HIV-uninfected children (Wilkinson and Davies, 1998; Rekha and 
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Swaminathan, 2007). HIV increases the incidence of TB and in Sub-Saharan Africa, a region with 
very high HIV rates, the incidence is growing at approximately 4% per annum (Maher et al. 2005). Of 
all the opportunistic co-infections affecting HIV-infected children TB is the most common (Williams 
and Dye, 2003; Ruxrungtham and Phanuphak, 2001; Swaminathan, 2004). The proportion of smear 
negative TB and extrapulmonary TB is higher among HIV-infected patients (WHO, 2004) making the 
diagnosis of TB more difficult compared to that in HIV-uninfected patients. 
The clinical presentation of TB as with many other opportunistic infections in the face of 
immunodeficiency is very variable depending on the level of immunodeficiency (Tantisiriwat & 
Powderly, 1999; Macdougall, 1999) and this poses serious diagnostic difficulties (Graham & 
Chaisson, 1993; Pape, 2004; Woldehanna & Volmink, 2004; Maher et al. 2005; Keshinro & Ya Diul, 
2006). Although TB diagnosis in HIV-infected adults is difficult (Reid and Shah, 2009), authorities 
generally agree that TB diagnosis in HIV-infected children is even more challenging (DOH, 2000; 
Newton et al. 2008). Some of the reasons for this are the paucibacillary (Chakraborty & Shingadia, 
2007) nature of the disease, the fact that children less than 10 years do not easily produce sputum and 
that there are more cases of disseminated TB (Mofenson et al. 2004; Chakraborty & Shingadia, 2007). 
These and other factors prompted the National Department of Health, South Africa (2000) to develop 
guidelines for diagnosis of TB in children. Diagnostic work up includes the tuberculin skin test, chest 
x-ray, history of contact with a suspicious TB case and clinical features that include cough for more 
than 2 weeks, chest pain and failure to thrive as depicted on the Road to Health Card (RTHC) without 
alternative explanation, recurrent lower respiratory tract infections not responding to antibiotics, 
painless matted cervical lymph nodes, more than a single episode of fever without alternative 
explanation, constitutional symptoms like fever, general body weakness, diarrhea, tachycardia and 
vomiting.   
The WHO is currently evaluating and endorsing several new laboratory ways of diagnosing TB. These 
include the liquid culture and rapid species identification which provide shorter turn-around times and 
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are more sensitive than traditional direct smear microscopy and TB culture currently being employed 
in most high TB burdened developing countries. The molecular line probe assay is for detecting TB 
bacteria and identifying susceptibility to isoniazid/rifampicin in smear-positive sputum samples. 
Nucleic acid amplification techniques such as the Gene Xpert have higher sensitivity than sputum 
smear microscopy and can provide a diagnosis of Mycobacterium tuberculosis and identify resistance 
to rifampicin and isoniazid in 90 minutes. The Gene Xpert could assist to more rapidly diagnose 
Mycobacterium tuberculosis complex and differentiate it from nontuberculous mycobacterial 
infections and might therefore be beneficial to diagnosis of TB in children when sputum samples can 
be obtained.  
BCG disease presents a special challenge to the diagnosis of TB disease in immunocompromised 
children in that it cannot be distinguished symptomatically from TB disease (Hesseling et al. 2003) 
and this difficulty is worsened by the fact that our laboratories do not routinely perform polymerase 
chain reaction (PCR) on samples from patients and the new TB diagnostic tools have not been 
implemented on a wider scale (WHO, 2008) to speciate the different mycobacterial strains. It presents 
in the following main forms, (1) the localized disease which may present as abscesses, ulceration or 
fistula at or around the vaccination site (2) as regional disease with ipsilateral axillary lymphadenitis 
and (3) the disseminated disease where sites beyond the satellite node are involved (Fallo et al, 2005; 
Hesseling et al, 2006). In an assessment of baseline factors that influence either the development of 
BCG complications or not in HIV-infected infants, one study found that only very low CD4 
percentage (13.6+/-11) was associated (p<0.01) and not the viral load, the disease stage nor the mean 
follow-up time (Fallo et al. 2005).  
The position of WHO on BCG is that it should not be given to known HIV-infected children 
regardless of symptoms and degree of immunocompromise but in children whose HIV status is 
unknown BCG should be given in all asymptomatic children at birth irrespective of HIV exposure 
status (WHO, 2007). For programmatic reasons, International Union against Tuberculosis and Lung 
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Diseases (IUTLD) BCG Working Group supports this revised WHO BCG vaccination policy, in 
countries highly endemic for TB until all programs are in place for implementing selective deferral of 
HIV-exposed infants (Hesseling et al. 2008). This is unfortunately the practical situation in most 
developing countries where the burden of HIV and TB are very high, screening for TB in babies is 
complex, PMTCT coverage is still behind and HIV testing is done around six weeks after birth in the 
public sector. It therefore means that almost all children are vaccinated before their HIV status is 
known although this is not the ideal. BCG vaccination coverage at birth in 2008 was around 89% 
globally and in the Afro region it ranged from 60 to 89% between 1990 and 2008 (WHO, 2009). It 
protects against severe forms of TB especially TB meningitis and disseminated TB but its efficacy 
was variable in different studies ranging from 65 to 85% in HIV uninfected children (Trunz, Fine & 
Dye, 2006). In HIV-infected children the benefits of BCG vaccination is doubted by other evidence. 
In Argentina, there was no difference in the frequency of TB disease in HIV-infected children among 
those vaccinated and those who were not (Fallo et al. 2005) raising the need for further prospective 
randomized clinical trials to establish the merits and demerits of BCG at birth policy.  
Impact of immune status, ART and previous TB on the incidence of TB: 
  
Retrospective studies have reported reduced incidence (Walters et al. 2008; Mhlongo et al. 2004; 
Miranda et al. 2007; Martinson et al. 2006) and reduced mortality (Walters et al. 2008) due to TB 
among children on ART compared to those who were not.  
Mathematical modeling suggested that a big population coverage (greater than 75%) and high 
adherence levels would be required to effectively reduce TB if ART is started early in HIV disease 
(Currie et al. 2003; Atun et al. 2007) and that universal testing with prompt ART initiation would 
reduce HIV incidence and mortality to less than one case per thousand within ten years of 
implementation and therefore reduce incidence of TB (Granich et al. 2009).  
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Seyler et al. (2005) concluded after multivariate analysis that the only risk factor for TB during ART 
is previous TB. Some authorities argue that the study was biased as the population composition was 
too narrow, composed of patients with advanced clinical HIV disease and advanced 
immunodeficiency which limited the applicability of multivariate modeling for the two important 
potentially confounding factors in the study, the baseline CD4 count and the baseline clinical stage of 
the disease (Lawn, Badri & Wood, 2005). 
In Cape Town, Lawn, Badri & Wood (2005) concluded that the ongoing risk of TB is dependent upon 
the nadir CD4 count and the clinical advancement of the HIV disease and past TB was not a risk 
factor.  
Martinson et al. (2006) found a lower incidence of TB (1.76 per 100 child years) among children 
whose viral loads were less than 400 copies per milliliter (ml) while it increased with increasing viral 
loads and that ART protects children from TB. 
Immune reconstitution:  
 
TB disease can occur early after starting ART. It has been shown in both high income and low 
resource settings that the incidence of TB is highest in the first three months of starting ART (Lawn et 
al. 2008; Chakraborty & Shingadia, 2007; Bonnet et al. 2006) and thereafter it falls rapidly and 
remains steady at lower rates (Lawn et al. 2008). 
ART improves TB specific immune responses and restores the manifestations of TB that were lost 
during immunosuppression (Lawn, Badri & Wood, 2005; Lawn, Bekker & Wood, 2005). Immune 
reconstitution inflammatory syndrome (IRIS) is commonly associated with mycobacterial infections, 
mainly BCG, Mycobacterium tuberculosis and non-tuberculous mycobacteria (Boulware, Callans & 
Pahwa, 2008; Smith et al. 2009). Two main mechanisms have been speculated to be possible 
explanations for IRIS in children, one and more important in younger children and infants being that 
of unmasking of a subclinical opportunistic infection or inflammation in early ART, and two, a 
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paradoxical response where there is resurgence of clinical manifestations of a pre-ART infection or 
inflammatory reaction in early ART being more prominent in the older ages (Meintjies & Davies, 
2008; Boulware, Callans & Pahwa, 2008). A Thai study reported immune reconstitution syndrome 
caused by nontuberculous mycobacterial (NTM) infection in 9 of 153 (5.9%) HIV-infected children 2 
to 26 weeks after initiation of ART. The clinical syndrome included fever and dyspnea (2 children), 
fever and abdominal pain (3), subcutaneous nodules or suppurative lymphadenitis (4) and the 
causative species were Mycobacterium avium (4), Mycobacterium scrofulaceum (3), Mycobacterium 
kansasii (1) and Mycobacterium simiae (1) (Puthanakit et al. 2006). 
ART/antimycobacterial co-treatment:  
 
There is very sparse pharmacokinetic data especially in children to direct the optimal doses of 
ART/antimycobacterial cotreatments and mostly such therapy is being guided by extrapolation from 
adult data. A recent South African study limited by the sample size showed that doubling the dose of 
the Kaletra which is done in adults on rifampicin-based antimycobacterial treatment in 
ART/antimycobacterial co-treatment achieves sub-therapeautic Kaletra levels if done in children 
(McIlleron et al. 2009). They recommended the addition of extra ritonavir to further boost the Kaletra. 
Evidence from a South African prospective study has shown that nevirapine-based ART co-
administered with rifampicin-based antimycobacterial treatment has inferior virological outcomes 
compared to efavirenz-based ART and rifampicin-based antimycobacterial treatment (Boulle et al. 
2008). In Thailand a retrospective study (Manosuthi et al. 2008) showed that at 48 weeks subjects 
who received nevirapine-based ART and rifampicin-based antimycobacterial treatment (n=111) had 
inferior virological outcomes (viral load less than 50 copies) than efavirenz-based ART and 
rifampicin-based antimycobacterial treatment (n=77), (77.9% versus 67.9%) and that the rate of ART 
discontinuation due to side effects was higher among those who received nevirapine-based ART and 
rifampicin-based antimycobacterial treatment (7.2%) compared to those who received efavirenz-based 
ART and antimycobacterial treatment (none) although it was not statistically significant (p=0.084). A 
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retrospective cohort study in Botswana (Shipton et al. 2009) reported similar virological outcomes 
(viral load less than 400 copies) at one year between those who received ART alone, either nevirapine 
or efavirenz based NNRTI backbone (n=155) and those that received ART and antimycobacterial 
treatment (n=155) (82% versus 91%, p=0.28) but the trend towards hepatotoxicity was more among 
the later (9% versus 3%, p=0.05).   
Unfortunately, in the South African public sector context, especially in centers other than tertiary, for 
children under three years of age or less than 10 kilograms (kg) weight, the options for ART regimens 
is limited to only two NRTIs (lamivudine and stavudine/zidovudine/abacavir) and kaletra (DOH, 
2005) compromising the potential of constructing a second line regimen (WHO, 2008). Although 
recommended conditionally by the WHO for first line use where kaletra use is not feasible because of 
cold chain requirements and affordability (WHO, 2008), in South Africa nevirapine is generally not 
given due to concern about the possibility of resistance following the single dose exposure to 
nevirapine provided to HIV exposed babies during prevention of mother to child transmission 
(PMTCT) which is now a universal practice in the country. Efavirenz is not given because of lack of 
evidence of efficacy and toxicity in children less than three years. The major challenge is now to 
establish the safe and efficacious doses of kaletra and efavirenz during ART/antimycobacterial co-
treatment to be used in the very young children now that there is going to be an increased number of 
infants and young children on ART following new data and recommendations (Violari et al. 2008; 
WHO, 2008).  
CHAPTER 3: METHODOLOGY 
 
Aim: 
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To describe the prevalence of antimycobacterial treatment among HIV-infected children receiving 
HIV care at the time of starting ART and the antimycobacterial treatment-free survival after ART 
initiation. 
Objectives: 
  
1. To describe the proportion of children receiving antimycobacterial treatment at start of ART. 
2. To describe the two year antimycobacterial treatment-free survival of children after 
commencing ART. 
3. To determine whether selected pre-ART factors predict which children will require 
ART/antimycobacterial co-treatment. 
Design and Setting: 
 
This was a retrospective cohort study involving record reviews of all eligible children (see below) 
started on ART in the HSCC in the period 1
st
 April 2004 to 1st April 2008. Antimycobacterial 
treatment was examined as the outcome and not TB disease because of the difficulty of diagnosing TB 
disease in children and the fact that antimycobacterial treatment was not only given for TB disease but 
also for BCG disease, for mycobacterium avium complex (MAC) and for other mycobacteria other 
than TB (MOTT) but in the HSCC electronic database that was used, the reason for antimycobacterial 
treatment was not clearly delineated. If an antimycobacterial treatment warranting condition was 
suspected, children were initiated onto antimycobacterial treatment (and this was indicated as TB 
treatment in the database and no mention of the specific medication used was done making it 
impossible for one to attempt to differentiate the mycobacteria from each other). Although medication 
such as azithromycin, ciprofloxacin and clarithromycin were used in cases where MAC was isolated, 
no mention of this treatment was evident in the database and therefore the mention of ‗TB treatment‘ 
in the database referred to all antimycobacterial treatment (see sample of database in annexure). The 
same argument applied for BCGosis and BCG IRIS. It was therefore impossible for the author to 
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differentiate different mycobacteria based on the medications used. The confidence of the clinician 
that antimycobacterial treatment was needed for a child was taken as confirmation that the condition 
was indeed present.  
The data was entered onto excel database by trained data entry clerks who in turn received paper-
based data from the treating physicians. The quality of the data was frequently checked by the data 
manager who works closely with the resident epidemiologist to double check any data entry queries 
and to clean the data.  
Routine care at HSCC: 
 
HSCC caters for the biggest number of public sector pediatric HIV patients compared to any other 
childrens‘ HIV clinic in South Africa. It is located in a tertiary academic centre, Chris Hani 
Baragwanath hospital (CHBH), in Soweto. It caters for children that come as referrals from the clinics 
in the Johannesburg metropolis predominantly the west and southern Johannesburg areas, children 
diagnosed HIV-infected in the main CHBH hospital wards, HIV-infected children referred from 
private nursing homes and also for children brought directly from the community and then tested 
HIV-infected. It offers both primary health care services and specialist services. Its staff range from 
community counselors, dieticians, social workers, psychologists, administrators, data clerks, 
epidemiologists, nurses, researchers, pharmacists, medical officers and specialist pediatricians and the 
patients range from infants to adolescents.  
Children were generally started on first line ART according to the national ART guidelines of South 
Africa (DOH, 2005). This consisted of two NRTIs, specifically stavudine (D4T) and lamivudine 
(3TC), and one NNRTI (efavirenz) in children above the age of three years and weight above 10 kg or 
two NRTIs (stated above) and the PI, kaletra in children below the age of 3 years or less than 10 kg. If 
a child was started before the age of 3 years on a kaletra-based regimen there was generally no change 
in the regimen after they attained the 3 year age or 10 kg cut off point unless there were specific 
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indications such as poor tolerance or development of side effects. If lipodystrophy or hyperlactatemia 
occurred, D4T would be replaced with zidovudine (AZT) or abacavir (ABC). If hypercholesterolemia 
occurred, kaletra would be substituted with efavirenz. Changes within the first line were prompted by 
events like the development of side effects and intolerance to medication while a total change to 
second line would happen with virological failure sometimes confirmed by genotypic resistance 
testing done only on those cases suspected to be harboring resistance based on virological and 
immunological profiles. Switching to second line therapy was dependent upon the limited ART 
options for children. For children who needed ART/antimycobacterial co-treatment and were above 
the age 3 years or 10kg limits stated above, their first line ART regimen was generally not adjusted. 
For those that were below this cut off, kaletra dosing was adjusted upwards depending on the body 
surface area. It is worthwhile mentioning that the time period spanned by this study is before 
emergence of new data showing the inadequate dosing of kaletra in children on 
ART/Antimycobacterial co-treatment (McIlleron et al. 2009). 
Before starting ART, each child had to be confirmed HIV-infected by either the enzyme linked 
immunosorbent assay (ELISA) test for children above 18 months of age or the deoxyribonucleic acid 
polymerase chain reaction (DNA PCR) test for those below 18 months of age. Baseline assessments 
were done on each patient before starting ART. These included a thorough history and examination to 
stage the patient according to the WHO HIV staging system and to exclude active TB disease (DOH, 
2000) and any other opportunistic infections. For those patients diagnosed as having TB disease or 
other mycobacterial disease on either clinical grounds or laboratory confirmation, antimycobacterial 
treatment would be instituted straight away and ART usually delayed for at least two weeks 
depending on the level of immunocompromise and the collective physicians‘ opinion. Baseline 
assessments on all patients included weight and height measurements, chest x-ray (CXR), CD4 count, 
viral load (VL), full blood count (FBC) and alanine transferase (ALT). Any other additional tests were 
done based on specific medical indications. 
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During the period in question, children with clinically suspected active TB disease or other 
mycobacterial event were generally not started on ART but taken through a more rigorous series of 
investigations for TB such as sputum or gastric washings for TB microscopy, TB culture and 
sensitivity and TB blood culture (TB bactec), tuberculin skin test (TST) and radiological tests. 
Histological diagnosis was also carried out for cases especially of suspicious TB lymphadenitis and 
TB abscesses. Diagnosis of TB disease depended upon a confirmation of mycobacterium isolated 
from some of the above tests or was based on the criteria for diagnosing TB disease in children (DOH, 
2000; WHO, 2006) and also the clinicians‘ suspicion if tests were negative. The later was always done 
in consultation with the specialist resident paediatrician. 
For children below eight years of age whose ailment warranted antimycobacterial therapy, the 
medications used were for a total duration of 6 months rifampicin, isoniazid and pyrazinamide  
(ethambutol was added to this intensive phase if children were above eight years of age) for the first 
two months of intensive phase and rifampicin and isoniazid for the continuation phase of four months. 
Other antimycobacterial agents that were used were azithromycin, clarithromycin, amikacin and 
ciprofloxacin for MOTT. These were used for a more prolonged period of at least 18 months guided 
by the clinical response to treatment and the follow up cultures for mycobacterial isolation.     
Children with suspicious BCG disease after starting ART would be given three drug 
antimycobacterial treatment consisting of rifampicin, isoniazid and ethambutol for six months if the 
area of induration was greater than fifteen millimeters (mm) on the TST for localized BCG disease or 
if there was evidence of disseminated BCG disease (BCG-osis). If the TST was less than fifteen mm 
they would be treated with steroids and investigated for active TB in the ways described above.  
Inclusion criteria: 
  
 Children less than 15 years at ART initiation 
 Started ART in the period 1st April 2004 to 1st April 2008 (last ART start date)  
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 Presumed ART naïve at the time of first contact with HSCC 
Population and Sample: 
   
Records of all children started on ART at the HSCC programme in the period 1
st
 April 2004 to 1
st
 
April 2008 were accessed from the clinic database.  
Covariates:  
 
Demographic: Age at start of HAART.  
Clinical: Baseline WHO stage of HIV disease, baseline CD4 percentage, baseline normalized weight 
for age z scores (waz), baseline viral load. 
Other variables in the database 
Previous TB treatment was left out of the whole data analysis although it was recorded in the database 
because it was deemed unobjective in this particular study. This was because it was difficult to 
ascertain the previous basis of diagnosis, whether it was really TB or any other mycobacterial events, 
whether the child completed treatment or not, and where the child got the treatment from as most of 
this information was obtained from the child‘s guardian who was not necessarily the one who was 
caring for the child before especially in cases of adopted children or those who were coming from 
children‘s homes and these constituted a significant number. Although IPT would probably have 
altered the risk of developing mycobacterial events, it was not emphasized in the HSCC practice at the 
time in question and practitioners were generally not prescribing it once children were started on 
ART. Therefore although this variable was included in the database it was left out of this analysis for 
that reason. Although it is known as a risk factor for TB in children, maternal or close contacts TB 
status were not included in the HSCC database and in this analysis it was therefore not included 
among the risk factors. The other variables in the database were deemed irrelevant for the study in 
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question and these variables are only mentioned and defined in annex 1 below because they are too 
many to mention here. 
The CD4 and viral load bloods were done and recorded at six months intervals and therefore although 
in some literature (Hermans et al. 2010) it has been reported the CD4 and or the viral load at the time 
of TB was significant risk factor it was impossible for the records to tell the CD4 or viral loads at the 
time of mycobacterial events in the current analysis and any such analysis would have probably 
misrepresented the truths. For instance if a child developed a mycobacterial event in the second month 
from the last recorded CD4 or viral load the next CD4 and viral loads were only done and recorded in 
the sixth month in the routine HSCC practice. 
It was not possible to retrospectively tell the type of mycobacterial event that led to the child receiving 
antimycobacterial treatment from the HSCC database. Although some of this data was probably 
obtainable from the physical records made by the physicians, this attempt was not made because of 
the huge volumes of records that needed to be compiled and analyzed in the limited time of the 
research.   
Ethics and Confidentiality: 
  
Approval for use of data from the ART database of the HSCC for retrospective studies was granted by 
the University of the Witwatersrand ethics committee as part of ‗The International Epidemiological 
Database to Evaluate AIDS (IeDEA) Collaboration‘ and from the Ethics Committee of the University 
of the Western Cape (UWC).  
Data analysis: 
  
The SAS software package (SAS version 9.0 (SAS, Cary, North Carolina, USA)) was used to clean 
and analyze the HSCC database. Period of follow-up commenced at start of ART and ended at the 
closure of the database on 11
th
 April 2008 for children who did not go on antimycobacterial treatment. 
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Children exited follow-up at date of first antimycobacterial treatment recorded, database censoring 
occurred at date of last visit if child was lost to follow-up or transferred or died. Kaplan-Meier (KM) 
models were used to determine the cumulative probabilities of being on antimycobacterial treatment 
among children who started ART without antimycobacterial treatment and also to determine 
associations between selected pretreatment factors and future antimycobacterial treatment. KM curves 
were plotted for antimycobacterial treatment-free survival in general and then stratified by baseline 
risk factors. The Log rank test was used for comparison. Antimycobacterial treatment-free survival 
was defined as the time from start of ART to the date of antimycobacterial treatment or date of last 
clinic visit if lost to follow-up. Logistic regression modeling was then fitted to determine the 
independent associations of each covariate with the antimycobacterial treatment using the chi-squired 
test and the odds ratios as measures of association and risk respectively. A p-value <0.05 was 
considered statistically significant.  
Definitions: 
The baseline CD4 percentage was defined as the CD4 percentage measured within ninety days prior to 
starting ART and if more than one record was found in the database the one closest to ART start date 
was taken and used in analysis. A similar definition was used for baseline viral load being defined as 
the viral load measured within ninety days prior to starting ART and if more than one record was 
found in the database the one closest to ART start date was taken and used in analysis. The baseline 
WAZ was defined as the WAZ measured within ninety days prior to starting ART and if more than 
one record was found in the database the one closest to ART start date was taken and used in analysis. 
The baseline WHO stage was defined as the lowest WHO stage achieved before ART was initiated 
according to the WHO staging definitions for HIV (with stage 4 being the lowest and stage 1 being he 
highest in that ascending order). The WHO stages 3 and 4 were combined and defined as advanced 
disease since the WHO staging system was only ending at stage 3 before latest WHO guidelines 
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introduced the stage 4 in children and therefore the system divided the cohort (for HSCC the new 
system was introduced after 1
st
 October 2005 using the draft WHO guidelines). 
Age was defined as the age in days at the start of ART. The date of antimycobacterial treatment was 
estimated as the first date of the mention of antimycobacterial treatment in the database at or after the 
start of ART. Viral load <400 copies/ml was defined as suppressed, CD4% was categorized into three 
groups (1) less than 15%, (2) between 15 and 25% and (3) above 25% in accordance with WHO 
criteria for grading immunosuppression. Waz was categorized using standard clinical definitions of 
Centers for Disease Control and Prevention (CDC), (2000) of severe (< -3), moderate (between -2 and 
-3), mild (between -2 and -1) and normal (above -1). 
Frequency distributions for each variable were done and examined and obvious errors that occurred in 
data entry detected. Observations with missing or outlying values were censored during the analysis of 
the variables where such were encountered. Due to time constraints, no effort was made to counter-
examine the electronic database against the actual patient‘s files but because of the continuous 
cleaning and updating of the database for the purpose of other research being done it is hoped that the 
data is generally representative of the truth. 
CHAPTER 4: RESULTS 
 
Figure1: Flow diagram for eligibility criteria 
 
 
 
 
 
 
All eligible children 
who started ART 
1941 
Not on antitubercular 
treatment  
At start of ART1423 
1423 
On antitubercular treatment 
At start of ART 
518 
No further analysis Analyzed further for  
Predictors of future 
 antitubercular treatment 
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A total of 1941 children met the criteria for enrolment. The profile of the whole cohort of children 
meeting enrollment criteria in terms of their pre-treatment characteristics is as shown Table 1. Among 
those who met the criteria 1423 (73.3%) were not on antimycobacterial treatment at the time of 
starting ART and these are the ones that were further analyzed for antimycobacterial treatment-free 
survival and risk factors for future antimycobacterial treatment. No further analysis was done among 
those 518 who were enrolled while on antimycobacterial therapy (26.7%). 
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Table 1: The profile of baseline characteristics: 
   
Characteristic Category  N (%) frequency   
   
<1  246 (12.7) 
1-3 424 (21.8) 
3<x<=5  343 (17.7) 
Age (years) % 
5<x<=15 928 (47.8) 
Median age (days) IQR 1728 (754-2771) 1941 
   
<401 35 (1.8) 
401-750 000 1372 (70.7) 
>750 000 371 (19.1) 
Viral load (copies/ml) 
Missing  163 (8.4) 
median Viral load (copies/ml) IQR 150000 (40000-590000) 1941 
   
<-3 523 (26.9) 
-3<z<-2 430 (22.2) 
-2<z<-1 528 (27.2) 
Weight for age (Z- scores) 
>-1 460 (23.7) 
Median WAZ (IQR) -1.97 (-3.1 to -1.0) 1941 
   
0-14.9 1320 (68.0) 
15-24.9 414 (21.3) 
CD4 percent %  
>25 105 (5.4) 
 Missing  102 (5.3) 
Median CD4 % (IQR)  11.2  (6.9-15.7) 1941 
   
1 140 (7.2) 
2 435 (22.4) 
3 & 4 1244 (64.1) 
WHO stage  
Missing  122 (6.3) 
   
Yes  518 (26.7)  antitubercular treatment at ART start 
No 1423 (73.3)  
 
 
By the time children start ART the prevalence of antimycobacterial treatment was 518/1941 {26.7%, 
(95% CI: 24.7-28.7)}. Most children started ART when they already had advanced HIV disease 
(64.1% when WHO stage 3 and 4) and (68% when CD4 less than 15%) only 5.4% of children started 
ART when the CD4 was above 25% (median CD4 11.2%, interquartile range (IQR), 6.9-15.7%). 
Approximately 26.9% of children started ART when they were severely malnourished (baseline waz 
less than -3). The median baseline waz was -1.97 (IQR, -3.1 to -1.0). Most of the children that started 
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ART were older and fell in the age range five to fifteen years (47.8%) while 12.7% were less than one 
year. The median baseline age in days was 1728 (IQR, 754-2771). 
 
Table 2: KM cumulative probability of antimycobaterial treatment at 3, 12 and 24 months 
post ART initiation 
Time point Antimycobacterial 
treatment (%) 
95% Confidence 
interval (%) 
   
Prevalence of antimycobacterial treatment at ART 
start n/N (%) 
     518/1941 (26.7)                  24.7-28.7 
   
New antimycobacterial treatment post ART start 
(0-3 months) 
     4.6                  4.1-5.2 
   
New antimycobacterial treatment post ART start 
(0-12 months) 
     18.1                  17.0-19.2 
   
New antimycobacterial treatment post ART start 
(0-24 months) 
     24.0                  21.9-25.3 
 
 
Table 2 shows the prevalence of  antimycobacterial treatment  at start of ART (26.7%) and the 
cumulative proportions of children started on antimycobacterial treatment during the first 3, 12 and 24 
months after initiating ART (KM analysis). The cumulative probability of ART/antimycobacterial co-
treatment among children who started ART without antimycobacterial treatment was 4.6% in the first 
3 months after starting ART and increased to 18% at the end of first year and thereafter the increase 
was gradual to 24% at 2 years. 
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Table 3: The KM cumulative probability of antimycobacterial treatment (0-3 months) 
among those without antimycobacterial treatment at ART start stratified by baseline 
characteristics 
Variable 
Catego
ry 
Number 
at risk 
New 
mycobacterial 
Rx by 3 mo 
Cumul probab of 
mycobacterial Rx by 3 
mo 
log rank 
p-value 
      
Age (years) <1 153 12 13 
0.0004 
 
1 to 3 249 15 9 
>3 to 5 244 12 7 
>5 to 
15 
683 24 4 
      
Viral Load 
(copies/ml) 
<400 17 0 0 
0.0162 
 
400 to 
750000 
975 42 6 
>75000
0 
228 13 8 
      
Weight for 
age (z score) 
<-3 299 26 12 
<0.0001 
 
-3<z<-2 294 11 5 
-2<z<-1 386 17 6 
>-1 350 9 4 
      
CD4 (%) >25 76 3 5 
0.213 
 
15-24.9 321 12 5 
<15 873 42 7 
      
WHO stage Stage 1 123 1 0.8 
<0.0001 
 
Stage 2 356 9 3 
Stage 3 756 50 10 
 
 
 
With the exception of baseline CD4 (p = 0.213) all other baseline factors were statistically significant 
risk factors for future antimycobacterial treatment (log rank p < 0.05) among those who started ART 
without antimycobacterial treatment. The cumulative probability of ART/antimycobacterial co-
treatment decreased with increasing age. There were increasing chances of co-treatment among those 
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who started ART with advanced malnutrition, those with very high viral loads and those who started 
ART when they had advanced clinical stage of the disease.  
 
Table 4: The KM cumulative probability of antimycobacterial treatment (0-12 months) among 
those without antimycobacterial treatment at ART start stratified by baseline characteristics 
Variable 
Categor
y 
Number 
at risk 
New mycobacterial 
Rx by 12 mo 
Cumul probab of 
mycobacterial Rx by 12 
mo 
log rank 
p-value 
      
Age (years) <1 173 70 52 
<0.0001 
 
1 to 3 270 54 25 
>3 to 5 259 33 14 
>5 to 15 717 72 12 
      
Viral Load 
(copies/ml) 
<400 24 4 19 
<0.0001 
 
400 to 
750000 
1032 133 15 
>75000
0 
249 70 34 
      
Weight for 
age (z score) 
<-3 332 99 35 
<0.0001 
 
-3<z<-2 316 50 21 
-2<z<-1 409 53 15 
>-1 362 27 8 
      
CD4 (%) >25 85 18 30 
0.2046 
 
15-24.9 335 48 18 
<15 939 152 19 
      
WHO stage Stage 1 129 7 6 
<0.0001 
 
Stage 2 367 34 2 
Stage 3 814 172 26 
       
 
With the exception of baseline CD4 (p = 0.2046) all other baseline factors were statistically 
significant risk factors for future antimycobacterial treatment (log rank p < 0.0001) among those who 
started ART without antimycobacterial treatment.  
 
 
 
 
  33 
Table 5: The KM cumulative probability of antimycobacterial treatment (0-24 months) among 
those without antimycobacterial treatment at ART start stratified by baseline characteristics 
Variable 
Categor
y 
Number 
at risk 
New mycobacterial 
Rx by 24 mo 
Cumul probab of 
mycobacterial Rx by 24 
mo 
log rank 
p-value 
      
Age (years) <1 173 74 54 
<0.0001 
 
1 to 3 270 62 23 
>3 to 5 260 41 18 
>5 to 15 718 86 15 
Viral Load 
(copies/ml) 
<400 25 4 18 
<0.0001 
 
400 to 
750000 
1033 155 18 
>75000
0 
249 79 37 
Weight for 
age (z score) 
<-3 333 105 36 
<0.0001 
 
-3<z<-2 316 59 24 
-2<z<-1 410 62 18 
>-1 362 37 13 
CD4 (%) >25 85 18 26 
0.2046 
 
15-24.9 336 53 20 
<15 939 181 22 
WHO stage Stage 1 129 11 10 
<0.0001 
 
Stage 2 369 43 13 
Stage 3 814 189 30 
      
 
 
With the exception of baseline CD4 (p = 0.2137) all other baseline factors were statistically 
significant risk factors for future antimycobacterial treatment (log rank p < 0.0001) among those who 
started ART without antimycobacterial treatment.  
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FIGURE 2: 2-year antimycobacterial treatment-free survival function among children 
initiated ART without antimycobacterial treatment in period 01.04.2004-01.04.2008 
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Approximately 24% (95% CI: 21.9-25.3) of the children who started ART without antimycobacterial 
treatment had antimycobacterial treatment in the first 24 months of ART. From the shape of the KM 
plot above which is quite steep from time zero to about the mid of 300 and 400 days one can deduce 
that most mycobacterial events occurred within the first 12 months of starting ART. Thereafter the 
curve flattens out implying much reduced numbers of mycobacterial events.   
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FIGURE 3: 2-year antitubercular treatment-free survival distribution function among children 
initiated ART without antitubercular treatment in the period 01.04.2004-01.04.2008 stratified 
by baseline age categories (P<0.0001) 
 
                                                                 KEY: 
                                                                 _____________age < 1 year 
                                                                 _____________age 1 to 3 years 
                                                                 ____________age >3 to 5 years 
                                                                 _____________age >5 to 15 years 
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Children less than one year had significantly lower antimycobacterial treatment-free survival of 48% 
at 12 months and 46% (log rank p < 0.0001) by 24 months. The trend was also seen in the age group 
one to three years although the antimycobacterial treatment-free survival seemed to be much better 
than the former. Above the age group one to three years there seemed to be no significant difference 
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in the antimycobacterial treatment-free survival among the age groups. The KM curve was steepest in 
the first 12 months of starting ART implying the occurrence of most mycobacterial events happening 
in that period and thereafter there seemed to be a gradual decrease in the number of events as shown 
by the flattening of the curve (Figure 3). 
 
FIGURE 4: 2-year antitubercular treatment-free survival distribution function among children 
initiated ART without antitubercular treatment in the period 01.04.2004-01.04.2008 stratified 
by baseline CD4 percentage (P=0.2137)  
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There was no difference in antimycobacterial treatment-free survival between children whose baseline 
CD4 percentage was high (> 25%) and those whose CD4 percentage was very low (< 15%) (Log rank 
p = 0.213) (Figure 4). 
 
FIGURE 5: 2-year antitubercular treatment-free survival distribution function among children 
initiated ART without antitubercular treatment in the period 01.04.2004-01.04.2008 stratified 
by baseline viral loads (P<0.0001) 
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High baseline viral loads (> 750000) were significantly associated with reduced antimycobacterial 
treatment-free survival (log rank p < 0.0001) compared to those with lower viral loads (Figure 5). 
FIGURE 6: 2-year antitubercular treatment-free survival distribution function 
among children initiated ART without antitubercular treatment in the period 
01.04.2004-01.04.2008 at HSCC stratified by baseline weight for age (P<0.0001)  
KEY:  
_____________Weight for age greater than -1 
_____________ Weight for age between -2 and -1 
_____________ Weight for age between -3 and -2 
_____________ Weight for age less than -3 
FUTB-Follow up time to antiTB treatment initiation 
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Severe malnutrition (waz -3) was significantly associated with reduced antimycobacterial treatment-
free survival (log rank p < 0.0001) compared to those who had higher weight for age (Figure 6) with 
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only slight differences in the antimycobacterial treatment-free survival comparing those with waz in 
the -3 to -1 range relative to those with waz > -1 (log rank p < 0.0001).  
FIGURE 7: 2-year antitubercular treatment-free survival distribution function 
among children initiated ART without antitubercular treatment in the period 
01.04.2004-01.04.2008 stratified by baseline WHO stage of HIV (P<0.0001) 
KEY: 
________________WHO group 1 
________________WHO group 2 
________________WHO group 3 
FUTB-Follow up time to antiTB treatment initiation 
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Baseline advanced HIV disease (WHO stage 3 and 4) was significantly associated with a reduced 
antimycobacterial treatment-free survival compared to earlier disease stages (log rank p < 0.001).  
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Logistic regression modeling was then used determine the role of baseline characteristics as predictors 
of antimycobacterial treatment. The Likelihood Ratio Test (LRT) for global null hypothesis (Beta = 0) 
was statistically significant (P < 0.0001) showing that all the baseline characteristics put together were 
associated with future antimycobacterial treatment.  
Table 6: Results of maximum likelihood and odds ratios estimates for baseline factors and 
antitubercular treatment at 24 months. 
Characteristic Category Odds ratio (95 % CI) P-value 
    
Age (years) <1 3.665 (2.249-5.972)             <0.0001 
1 to 3 1.899 (1.242-2.905) 0.7394 
>3 to 5 1.545 (0.992-2.406) 0.3175 
>5 to 15  1.0  
    
Viral Load (copies/ml) <400 0.476 (0.127-1.777) 0.3592 
400 to 750000 0.759 (0.510-1.129) 0.7891 
>750000 1.0  
    
Weight for age (z score) <-3 2.235 (1.389-3.596) 0.0015 
-3<z<-2 1.686 (1.046-2.719) 0.2799 
-2<z<-1 1.191 (0.736-1.926) 0.1562 
>-1 1.0  
    
CD4 (%) >25 0.654 (0.350-1.221)               0.5604 
15-24.9 0.616 (0.420-0.902) 0.2260 
<15 1.0  
    
WHO stage Stage 1 0.466 (0.238-0.916) 0.2397 
Stage 2 0.486 (0.326-0.725) 0.1641 
 Stage 3 & 4 1.0  
 
 
From the results (Table 6) age less than one year {Odds ratio (OR): 3.7 (95% CI 2.2-6.0; p < 0.0001)} 
and very low weight for age (waz < -3) {OR; 2.2 (95% CI 1.4-3.6; p=0.0015)} were the two critical 
risk factors independently associated with future antimycobacterial treatment. For age above one year, 
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CD4 above 15%, waz >-2, WHO stage 1 & 2 and viral load below 750 000 the trend was towards 
protective from antimycobacterial treatment (p > 0.05). 
 
CHAPTER 5: DISCUSSION  
A previous study from adults in South Africa (Lawn et al. 2007) reported the prevalence of 
antimycobacterial treatment of 160/756 (21%) among patients (median age 33 years) starting ART in 
a clinic in Gugulethu, South Africa which was close to what was found in this study among children 
(26.7%). 
Data from children about the antimycobacterial treatment-free survival among those started ART 
without antimycobacterial treatment is scarce. There are no previous reports of cumulative probability 
of antimycobacterial treatment among children who started ART without antimycobacterial treatment 
but recent data has shown that the incidence of TB among children decreased with increasing time on 
ART from 18.9 per
 
100 person-years in the first 6 months to 5.3 per 100 person-years
 
after 12 months 
of ART (Edmonds, 2009). Similarly, quite recent data from Uganda among adults showed incident TB 
to also decrease with time from ART initiation with the incidence rates (95% CI) at 0–3, 3–6, 6–12 
and 12–24 months being 11.25 (9.58–13.21), 6.27 (4.99–7.87), 2.47 (1.87–3.36) and 1.02 (0.80–1.31), 
respectively (Hermans et al. 2010). A Senegalese study also reported similarly among adults that over 
the first 4 years on HAART, the annual incidence rate decreased regularly from 4.5 cases/100 P-Y 
[95% IC: 2.8 - 7.7] during the first year to 3.5 [1.9 – 6.5] the second year, 1.5 [0.6 - 4.1] the third year 
and to 0.4/100 P-Y [95% IC: 0.0 – 2.9] the fourth year (Etard et al, 2009). The current study is limited 
in that it cannot report on the incidence density rate of antimycobacterial treatment because of its 
design which cannot distinguish repeated cases of antimycobacterial treatment exposure while on 
ART. Besides the limitation of not knowing the level of adherence to ART among children in this 
cohort there is agreement with previous reports (Bekker et al. 2003; Lawn, Badri & Wood, 2005, 
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Hermans et al. 2010) that showed that the highest incidence of mycobacterial events was in the first 
year of ART compared to the later years (Figure 2).   
CD4 percentage: Higher baseline CD4 above 22% among children less than five years was 
associated with much better survival in general in a Thai study (Vanprapar et al. 2000). Retrospective 
reports from adults found a high risk of TB associated IRIS in patients with very low baseline CD4 
counts (Lawn, Badri & Wood, 2005; Lawn et al. 2007; Sirisanthana et al. 2004). Similar findings 
have been reported in recent Ugandan data that found incident TB among adults during ART was 
independently associated with baseline CD4 count of <50 cells/mm
3
 (hazard ratio [HR] 1.84 [1.25–
2.70], P = 0.002). Etard et al. (2009), in a prospective cohort also reported a low baseline CD4 being 
associated with early incident TB in Senegal. The current data suggests a protective role from 
antimycobacterial treatment events of higher baseline CD4 (above 15%) compared to below 15% 
although this was not statistically significant (p > 0.05) (Table 6). A prospective study that looked into 
the incidence of IRIS in Johannesburg reported TB as the commonest form of IRIS and it mainly 
affected those who started ART with advanced immunosuppression (Murdoch et al. 2008). Smith et 
al. 2008, concluded that CD4 percentage lower than 10% was a risk factor (OR 5.84, CI 1.72-19.8) for 
IRIS (mostly BCG-osis and TB) among young children after starting ART. Another South African 
study among children reported that IRIS occurred especially among those who were younger (median 
age 7 vs. 10 months, P = 0.007) with a lower CD4 cell percentage (median 13.9 vs. 19.2, P = 0.009) at 
HAART initiation than controls (Smith et al. 2009). A prospective study from South Africa also 
reported similarly that BCG IRIS risk was associated with lower baseline CD4 percentage among 
infants and most cases were diagnosed soon after initiating ART (Rabie et al. 2008). However, there 
is contradiction with Van Rossum et al. (2001) and Seyler et al. (2005) whose data suggested that the 
pre-treatment baseline CD4 was not a critical factor in determining future immune reconstitution and 
ability to fight diseases. The later study (Seyler et al. 2005) was limited in its generalisability by the 
narrow patient selection base which consisted mainly of patients with advanced HIV disease and 
therefore mostly low baseline CD4 counts. Among the selected baseline factors that influence either 
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the development of BCG  complications or not in HIV-infected infants, only very low CD4 
percentage (13.6+/-11) was associated (p<0.01) and not viral load, the disease stage nor the mean 
follow-up time (Fallo et al. 2005). The current study was limited by the small numbers of children in 
the CD4 category above 25% (only 6.8%). This was however unavoidable since the standard practice 
at the time emphasized starting ART when CD4 was less than 25% except in clinically advanced 
disease (DOH, 2005). A previous report from HSCC within the same period showed that MAC was 
commonest among children who had very low absolute CD4 count of less than 50 (Kleynhans et al, 
2008). The prevalence of MAC was found to be very low in this particular study (13/2354 or 0.55 
over a four year period between 2004 and 2007). 
Age group: The current study reports a lower antimycobacterial treatment-free survival among 
children less than one year of age compared to the age groups above. Smith et al. (2008) found age 
less than 6 months a significant risk factor (OR 4.5, CI 1.73-11.74) for IRIS mostly in the form of 
BCG-osis and TB disease. Possible reasons for the lower antimycobacterial treatment-free survival in 
the current study include the contribution of BCG disease, BCG IRIS, the increased difficulty in 
diagnosing TB disease in the very young children (Chakraborty & Shingadia, 2007; National 
Department of Health, 2000; Mofenson et al. 2004) and the raised index of suspicion generally taken 
by practitioners when dealing with this age group which likely pushed practitioners to treat many 
unconfirmed cases as TB disease. The overlapping features of HIV and TB disease especially in the 
very young children probably resulted in many HIV-infected children being put on antimycobacterial 
treatment compared to the older children in whom diagnosis of TB is less challenging. The higher 
rates of antimycobacterial treatment in this age group could also reflect the low immune response 
associated with infancy especially those whose household contacts had TB disease (infants are almost 
always in contact with adult caregivers increasing their susceptibility to infections). This was however 
difficult to assess in this study because of its design and because data on household contacts about TB 
was not included in the database. The contribution of BCG disease in particular was probably the 
biggest in this age group if one is to look at evidence from a similarly high TB/HIV burden setting 
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(Hesseling et al. 2009; Smith et al. 2009). Data from a multicentre surveillance prospective study 
among South African children less than one year suggested very high incidence of disseminated BCG 
disease per 100 000 BCG-vaccinated, HIV-infected infants which were as follows: 778 (95% 
confidence interval, CI: 361-1319) in 2004 (vertical HIV transmission rate: 10.4%); 1300 (95% CI: 
587-2290) in 2005 (transmission rate: 6.1%); and 1013 (95% CI: 377-1895) in 2006 (transmission 
rate: 5.4%) and the pooled incidence over the study period was 992 (95% CI: 567-1495) per 100 000 
(Hesseling et al. 2009). The Hesseling data however did not report on the influence of ART among 
the HIV-infected children since this could have possibly made a difference in the incidence of 
disseminated BCG disease and a further stratification is therefore another research question before 
concrete recommendations are made about BCG vaccination in high TB/HIV settings with high ART 
coverage. It is also possible that the Hesseling data included cases of BCG IRIS (since the only 
distinguishing tests carried out were tuberculous and non-tuberculous mycobacteria from the BCG 
Danish strain if indeed some of these children received ART.  
It is also possible although unquantifiable in the current data to conclude that some cases of 
mycobacterial events were due to BCG IRIS and TB IRIS especially considering data from other 
studies documenting high frequencies of such events in the first few months of ART (Smith et al. 
2009). A South African study reported that BCG reaction was most common occurring in 24/34 
(71%) children, primarily injection site lesions and/or ipsilateral axillary lymphadenitis with abscess 
(Smith et al. 2009). Subclinical TB was also possibly missed when children were started on ART 
because of diagnostic difficulties and these cases could have become overt TB cases soon after 
starting ART (unmasking TB) and therefore received antimycobacterial treatment. 
In the HSCC the practice was that (due to lack of diagnostic resources) once the practitioners were not 
sure after investigation proved negative for common opportunistic infections and there was poor 
response to conventional antibiotics but the clinical features still pointed towards TB disease, 
antimycobacterial treatment was started. Data on this fact was however not readily quantifiable in this 
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study because of its design. The contribution of MOTT could also have been a significant factor here. 
Since in the analysis the date closest to the first record of ‗antimycobacterial treatment‘ for a particular 
record was the only one used, for most children who were later diagnosed with MOTT 
microbiologically or from histological specimens, they were initially started on standard 
antituberculous treatment while being investigated for MOTT and that standard treatment for TB was 
continued together with that for the MOTT. Kleynhans et al, 2008, from the HSCC in the same period 
of this data analysis reported that 9 out of the 12 cases (75%) that were confirmed as MAC were 
already on TB treatment by the time MAC was diagnosed. 
 WHO stage: The current study is suggesting a protective role of the early stages of HIV disease 
compared to stages 3 and 4 (combined in this case for reasons mentioned in the methods section) 
although this was not statistically significant (p > 0.05). This is also corroborated by some reports 
from adults that observed higher incidences of TB among patients who started ART with very 
advanced disease (Lawn, Badri & Wood, 2005; Badri, Wilson & Wood, 2002) compared to earlier 
WHO stages 1 and 2.  
Weight for age: Malnutrition at start of ART in this data was found to be an important risk factor for 
future antimycobacterial treatment. A South African prospective study among infants reported higher 
risk of BCG associated IRIS of low weight for age children (waz -1.5 (-2.5—0.5)), p=0,007 compared 
to children of higher waz at ART initiation (Rabie et al, 2008). A similar conclusion was drawn by 
another South African study, NEVEREST 2 (Smith et al. 2008), that higher risk of IRIS 
predominantly in the form of BCG-osis and TB were found among young children who were severely 
malnourished with weight for age z-score less than 2 standard deviations from the mean (OR 4.13, CI 
1.53-11.11). It should however be noted that the two studies above reported for children under one 
year of age. A stratification of waz and age group less than one year was going to be more appropriate 
in the current study in order for a fair comparison to be drawn with the infant studies mentioned 
above. Conclusions from these studies could however be a reflection of the behavior of attending 
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practitioners who probably after failing to get good results from treatment of other HIV related 
opportunistic infections causing failure to thrive would then prescribe antimycobacterial treatment. 
They should therefore be regarded cautiously. The WHO scoring system for diagnosis of TB in 
children is also brought into question (van Rheenen, 2002) here as 26% of the children in the current 
study started ART when they were already severely malnourished and therefore got a score of ‗4‘ and 
only needed few other parameters to get to ‗7‘ and become eligible for TB diagnosis and treatment.     
Viral loads: The current study is reporting a protective effect from mycobacterial events of baseline 
viral loads less than 750 000. There is also corroboration with the data from Smith et al. 2008 that 
showed that baseline viral loads above 750 000 were a risk factor for IRIS (mostly BCG-osis and TB 
disease) in the first few months of starting ART in the very young children. One can however 
extrapolate the data to mean an increased survival which agrees with the Thai data (Vanprapar et al. 
2000) that found a protective role of low viral loads (less than 500 000). However, the current study 
has a limitation of the small numbers of children with VL<400 and the very few events in this 
category also limited rational comparability with the rest of the viral load groups. A study that was 
limited by small sample size (Martinson et al. 2006) drew similar conclusions however of a lower 
incidence of TB among children with low viral loads.   
For reasons mentioned in the methods section the study did not analyze the CD4 level, viral load or 
the adherence to ART at the time children developed mycobacterial events although these have been 
shown in another study to be important predictors for development of mycobacterial events (Hermans 
et al. 2010). A study in the United Kingdom, a resource-rich low HIV prevalence setting, however 
showed no association between either the virological level or the immunological status at the time of 
TB diagnosis (Cohen et al. 2008). This later study was limited by the very small sample size 
comprising only 18 children.  
Another parameter that was not considered in this study was the importance of previous TB treatment 
on the development of new mycobacterial events although this was found in other study to have a 
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significant impact (Seyler et al. 2005). The reason for this omission was that it was difficult with the 
time given for the study for the researcher to individually visit the records of each patient, and 
therefore validate the data, to find if indeed they had been treated for TB, whether TB treatment was 
completed, the adherence to TB treatment, where the TB treatment was provided and how such a 
diagnosis was made.  
The fact that more than a quarter (26.7%) of all children who started ART were already on 
antimycobacterial treatment (WHO stage 3 and 4 disease) suggests that physicians in the HSCC were 
probably starting ART too late in the course of HIV disease among children and losing the 
opportunity of protection against TB that ART (Mhlongo et al. 2004; Lawn, Badri & Wood, 2005; 
Martinson et al. 2006; Miranda et al. 2007; Walters et al. 2008) could have provided had it been given 
earlier. 
However this data seems to suggest that there is a lot of subclinical TB which then manifests as 
clinical disease after starting ART as the immunity improves as shown by the exponential fall (Fig. 2) 
in the survival time to antimycobacterial treatment soon after commencing ART.  
The study‘s validity was good because there was careful follow up of all participants and careful 
recording of patient recruitment and selection, particularly reasons for exclusion. The HSCC database 
is also continuously cleaned and updated by trained data managers and epidemiologists because of so 
many studies concurrently using it. The study was reliable because clinicians at HSCC all used the 
same diagnostic protocol for TB disease, BCG disease and MAC in children and in all cases where 
one was not sure they consulted each other and also seeked the opinion of the resident paeditrician 
before offering treatment. Attempts to make the study more generalizable were made through 
widening the cohort inclusion criteria such as not limiting the CD4 levels, the viral load levels, the 
nutrition levels and the WHO stage of the disease to specific levels. 
Unlike TB incidence studies in resource limited countries, that are hugely limited by unreliable 
diagnostic tools, atypical clinical presentations, atypical radiological findings and the high number of 
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smear and culture negatives in HIV-infected children this study precludes these issues by looking at 
those who received antimycobacterial treatment for any reason. 
Limitations: The generalizability of the study was limited since clinicians in other settings might use 
different diagnostic protocols and a different management approach for TB events such as not giving 
antimycobacterial treatment in cases of suspicious BCG disease and immune reconstitution related to 
mycobacteria while others do. The other constraint to generalizability is that HSCC is well funded 
with highly trained HIV clinicians, a situation that is unusual in most public practices in South Africa 
and other African countries. For instance not all ART clinics outside tertiary research centres like 
HSCC measure baseline viral loads pre-ART. Although in South Africa the standard of practice is to 
measure viral loads at ART initiation in children, in Namibia for example, baseline viral loads are not 
recommended in the public sector. The findings are therefore a reflection of the HSCC practices in the 
period in question. 
Routinely collected data usually has missing data elements whose randomness can not be guaranteed 
and the data is generally not clean. Limits of routinely collected data was also through mistakes made 
at the point of data entry from paper onto the electronic format. This probably biased the findings of 
this study.  
As far as the field for antimycobacterial treatment was concerned the HSCC database for the follow 
up visits did not contain important variables like the basis of putting the patient on antimycobacterial 
treatment and date of antimycobacterial treatment commencement. This limited the possibility of 
calculating the incidence rate of antimycobacterial treatment due to the various reasons for which 
children received the treatment such as BCG disease and MAC (see above). There was also no record 
of MOTT or MAC in the database although these cases were seen and treated using antimycobacterial 
agents (Kleynhans et al, 2008). Following on this one can deduce that the data reported from HSCC to 
the national TB statistics was therefore not a true representation of the actual cases of TB disease 
since ‗TB treatment‘ was used as a proxy for TB disease in the database. This same argument may 
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also be applicable to other clinics‘ settings that report TB data for research purposes and for national 
statistics.  This can result in an overestimation of the statistics of TB disease because 
antimycobacterial treatment may be started for non-tuberculosis mycobacterial disease and in the very 
young children in many settings in South Africa antimycobacterial treatment is given for BCG disease 
and MOTT. 
There were losses to follow up due to death, transferring out and defaulting among cohort children. 
One would reasonably expect that more death happened among children who had a very low CD4 
percentage, high viral loads, severely malnourished and very advanced clinical stage of the disease 
and this probably confounded the results. A study that takes this into account is certainly necessary in 
future. However because the analysis was done using the KM plots, it is assumed that these losses 
were censored reasonably accurately. 
The use of the KM plots was however limited by the fact that the actual date of start of 
antimycobacterial treatment was not known and therefore was just estimated using the knowledge of 
the clinic operations that it was generally within a two week period after starting antimycobacterial 
treatment that the information was recorded in the database. 
Because the study was retrospective unavoidable errors of measurement could have occurred due to 
different measures being done by different scales and by different people and this was especially so 
for weight. Laboratory and human errors could also have taken place in the measurements of the CD4 
and viral loads and transportation of specimens to the laboratory and also during entry onto the 
electronic formats. 
A potentially great confounder of the study is the fact that the diagnosis of ‗antimycobacterial 
treatment warranting condition‘ was in addition to the tests mentioned above, dependent on the 
behavior of the attending physicians at a particular time and this could have changed over time during 
the cohort.  
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Another limitation of the use of survival analysis methods was that for those children who were put on 
antimycobacterial treatment after starting ART one could not ascertain for how many different times a 
particular child was on antimycobacterial treatment and certainly some children received 
antimycobacterial treatment more than once during the cohort period. So these children were counted 
only the first time they received antimycobacterial treatment and not the subsequent times and this 
probably reduced the extent of ART/antimycobacterial co-treatment which was the outcome of 
interest.  
This study has been limited in scope and excluded cases that were on TB treatment (26%) at the start 
of ART in order to accommodate the limited academic requirements for which it is primarily intended 
to serve. It is however appreciated that in order to truly reflect the bigger picture for purposes of 
inciting action on the part of stakeholders, it should have included this population. 
Besides the limitations, this study has shown that there is a high prevalence of antimycobacterial 
treatment among children at start of ART and that many children go on ART/antimycobacterial 
cotreatment especially soon after starting ART.  
CHAPTER 6: CONCLUSIONS   
The prevalence of antimycobacterial treatment at the time of starting ART was 518/1941 (26.7%, 95% 
CI: 24.7-28.7). Survival analysis suggested that children with high baseline viral load, advanced 
World Health Organization (WHO) stage of disease, very low normalized weight for age (waz) and 
very young age (less than one year) at start of ART had significantly reduced antimycobacterial 
treatment-free survival (log rank p < 0.05) in the first two years of starting ART. In the logistic 
regression model, age less than one year {Odds ratio (OR): 3.7 (95% CI: 2.4-5.9; p < 0.0001)} and 
very low weight for age Z-score (waz < -3) {OR; 2.2 (95% CI: 1.4-3.6; p = 0.0015)} were the two 
critical risk factors independently associated with future antimycobacterial treatment.  
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The high prevalence of antimycobacterial treatment at ART initiation underlines the importance of 
stricter screening to detect more mycobacterial events before starting ART. The results emphasize the 
need for a heightened and careful alertness for mycobacterial events among children after starting 
ART especially among the very young and those starting ART with severe malnutrition. Knowledge 
of the estimated antimycobacterial treatment-free survival and incidence helps policymakers in 
planning limited resources appropriately.  
To the HSCC this data prompts inclusion in the database of parameters like date of diagnosis of TB 
disease, the basis of diagnosis and the type of mycobacterial event that warranted antimycobacterial 
treatment which were missing at the time of the data recording for this particular study but are clearly 
important for future research purposes and action. The definition of antimycobacterial treatment in the 
HCSS database was also not conforming to the standard definition of six months antimycobacterial 
treatment for standard TB disease and this definitely needs to be urgently reviewed.  
To the scientific world the results suggest that we should do more research into better methods of 
prevention and diagnosis of mycobacterial events among children during HIV care. The high 
prevalence of ART/antimycobacterial co-treatment especially in children less than one year calls for 
an urgent need to give priority to research projects that attempt to find safer, more effective drugs for 
ART/antimycobacterial co-treatment and with low chances of negatively interacting with each other.  
Finally, but most importantly, the results of this study provide public health policymakers with a 
picture of the extent of ART/antimycobacterial co-treatment in children so that they can make 
informed decisions about the various needs of the children on co-treatment and in the formulation of 
guidelines for ART/antimycobacterial co-treatment especially among the very young where there are 
still very limited drug options and where diagnosis of mycobacterial events is especially challenging.  
More research into development of more accurate and quick diagnostic instruments for diagnosis of 
mycobacterial events in children is urgently required. 
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Annex 1. 
An outline of the variables in the database that were used in analysis 
InitialvisitiD: this was the identity number that the clinic would assign to a particular patient on their 
first visit to the clinic before starting ART.  
VisitDateTime: this were the dates that the patient came for consultations either on routine 
appointments or if there was a medical problem that needed attention by the clinic.  
PatientId: This was the identity number that the patient was given on the day ART was commenced. 
It was then used together with the initialvisitiD to identify and distinguish those on ART and this 
number was then subsequently used to identify the patient on future visits. 
DateOfBirth: This was the date that a particular patient was born. 
SexF: This was the gender of the patient female. 
SexM: This was the gender of the patient male. 
PopulationGroupAfrican: This was the population group of the patient that was of African origin. 
TransferredInOnArt: This was to identify those patients that were transferred in on ART from other 
ART sites to HSCC. 
ClinicStartedOnArt: This was to identify those patients that were transferred in on ART from local 
clinics like Zola clinic and Lilian Ngoyi clinic to HSCC. 
DateStartedOnArtPreviousClinic: This was the date ART was started for those patients who were 
started ART at other clinics before being integrated into the HSCC care. 
StartedOnArtInWardsCHB: This was to identify those patients that were transferred in on ART from 
Chris Hani Baragwanath wards to HSCC. 
ArtStartDate: This was the date that ART was started for those who started in HSCC. 
BodyWeight: This was the weight on a particular visit date. 
Temperature: This was the temperature on a particular visit date. 
Height: This was the height on a particular visit date. 
CD4Count: This was the CD4 count that was recorded on a particular visit date and this was done six 
monthly. 
ViralLoad: This was the viral load that was recorded on a particular visit date and this was done six 
monthly. 
CD4CountPercentage: This was the CD4 percentage that was recorded on a particular visit date and 
this was done six monthly. 
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TBStatusNoTB: This was if the patient had no TB on a particular visit date. 
TBStatusPreviousTB: This was an initial visit record to distinguish those who had a history of TB 
before enrolling in the HSCC. 
TBStatusInvestigate: This was for those patients who were presenting with symptoms of TB and 
were being investigated for TB. 
TBStatusMDRTB: This was for those patients that were on treatment for MDR-TB on a particular 
visit. 
TBStatusTBRx: This was for those patients that were on ‘TB treatment’ on a particular visit date.  
TBStatusProphylaxis: This was for patients who were on INH preventive therapy. 
TBRxINHStartDate: This was the date that INH preventive therapy was started. 
WhoClinicalStage1: This was the clinical stage 1 of HIV disease according to the standard WHO 
staging system. 
WhoClinicalStage2: This was the clinical stage 2 of HIV disease according to the standard WHO 
staging system. 
WhoClinicalStage3: This was the clinical stage 3 of HIV disease according to the standard WHO 
staging system. 
WhoClinicalStage4: This was the clinical stage 4 of HIV disease according to the standard WHO 
staging system. 
WhoClinicalStagCondition2: This was the clinical staging condition 2 as per the WHO staging 
protocol. 
WhoClinicalStagCondition3: This was the clinical staging condition 3 as per the WHO staging 
protocol. 
OtherMeds: This was any other medication that the patient was taking like cotrimoxazole. 
 
 
 
 
 
 
 
 
 
